Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials

The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants. In addition to questionnaires collected electronically, biometric monitoring technologies such as wearables, are now used by sponsors for drug approval—and require rigorous statistical analysis to generate acceptable clinical evidence.

We are now facing a question: What are the scientific, statistical, and regulatory frameworks for demonstrating the clinical validity of novel digital measures?

Access this Resource on Biometric Monitoring

To explore this question, Adriano Fontanari, Product Marketing at Alira Health, joined Bohdana Ratitch PhD, and her team as a contributor for the article “Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials.”

The paper “Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials” is part of work by the Digital Medicine Society (DiMe) research team, “Standardized statistical approaches to analyze and interpret BioMeTs data,” led by Yasaman Damestani, PhD.

Publications
Published on:
September 16, 2022
Written by:
Adriano Fontanari
About Alira Health

As experienced consultants, we can help you navigate the complex demands of clinical research, and deploying biometric monitoring solutions. We can provide your company with strategic advice and solutions designed to ensure success across the full product lifecycle.

Related news

Blog June 6, 2023
Content of Integrated Summaries of Efficacy and Safety (ISE/ISS): A Blog Series
Content of Integrated Summaries of Efficacy and Safety (ISE/ISS) blogs outline what elements are required for successful FDA submissions.
Biometrics ISE/ISS
Blog May 30, 2023
Specific Requirements for Integrated Summaries of Efficacy and Safety in FDA Submissions
This article in our Content of Integrated Summaries of Efficacy and Safety series focuses on specific requirements for FDA submissions.
Biometrics ISE/ISS
Blog May 19, 2023
Content of the Integrated Summaries of Efficacy and Safety
This article in our Content of ISE/ISS series focuses on what elements are required in the ISE/ISS to ensure a successful submission.
Biometrics ISE/ISS
Blog May 11, 2023
Introduction to Integrated Summaries of Efficacy and Safety
This article in our ISE ISS series focuses on the structure of the common technical document (CTD) and the objectives of the ISE/ISS.
Biometrics ISE/ISS
Events February 2, 2023
ACDM 2023
We are pleased to announce that we will be sponsoring and attending ACDM 2023. ACDM23 offers a full two-day program of expert speakers, specialist panels, workshops and debates which(...)
Clinical Data Science
Blog December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Blog December 14, 2022
How to Optimize Clinical Research with Patient Advisory Boards
Patient engagement is increasingly essential to all stages of product development—particularly clinical research.
Clinical Patient Advocacy Patient Centricity
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.